Furthermore, in addition to anti-PD-1 antibodies, the combination of nanoparticle-based PTT with anti-PD-L1 antibodies and anti-CTLA-4 antibodies also showed significant anti-tumor effects. This evidence concerns the gene CTLA4 and neoplasm.